# SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

> **NCT06927180** · PHASE2 · RECRUITING · sponsor: **Henan Cancer Hospital** · enrollment: 180 (estimated)

## Conditions studied

- Breast Cancer Early Stage Breast Cancer (Stage 1-3)

## Interventions

- **DRUG:** SHR-A1811
- **DRUG:** Pertuzumab
- **DRUG:** Albumin-Paclitaxel
- **DRUG:** Docetaxel
- **DRUG:** Carboplatin
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT06927180
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-16
- **Primary completion:** 2029-05-01
- **Final completion:** 2030-12-01
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2025-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06927180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06927180, "SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06927180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*